Publication
ESG and internal investigations: New compliance challenges
As ESG concerns have come to the forefront in different jurisdictions, the scope of these inquiries is expanding in kind.
Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies
The Life Sciences Lawyer Magazine
As the COVID pandemic lumbers on to its third year, there continues to be global disparities in access to the tools (i.e., vaccines and therapeutics) necessary to combat the pandemic.
A core reason behind this disparity is the developing world’s lack of access to the intellectual property (and technical know-how) required to manufacture these vital vaccines and therapeutics. In 2021, the United States announced that it would support the temporary waiver of intellectual property protections for COVID-19 vaccines under the Trade Related Aspects of Intellectual Property Rights (“TRIPS”) Agreement.
This article explores the current controversy around the waiver of intellectual property rights for COVID-19 vaccines and therapeutics and their implications for life sciences companies.
Read the full article from The Life Sciences Lawyer Magazine, "Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies."
Partner-in-Charge, San Francisco
Email
jason.novak@nortonrosefulbright.com
Recent publications
Publication
“First Ready, First Connected”: Reform to GB Electricity Grid Connections
The “First Ready, First Connected” reforms proposed by the Electricity System Operator (ESO), and which could be in place by the end of Q2 2025, aim to address existing issues with the application process for connections to the GB electricity grid.
Subscribe and stay up to date with the latest legal news, information and events . . .